GleamWall
中文EN

LCTX Lineage Cell Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 876343 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY0.2%
TTM net income YoY102.6%
TTM EPS YoY69.0%
Revenue 3-yr CAGR7.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-280.3%
Net margin16.2%
FCF margin-244.1%
EBITDA margin-273.3%

Returns

ROE3.9%
ROA1.8%
ROIC (approx.)-216.8%
Asset turnover0.11x

Leverage & solvency

Liabilities / assets34.1%
Debt / equity0.00x
Current ratio5.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-14.73x
Accruals ratio29.1%
Payout ratio—
Capex / revenue5.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$14.56M$9.50M
Cost of revenue—$334,000
Gross profit—$9.16M
R&D expense$17.73M$12.47M
SG&A expense$18.46M$18.17M
Operating income-$36.62M-$21.48M
Pretax income-$68.65M-$18.58M
Income tax-$5.28M$0
Net income-$63.53M-$18.61M
EBITDA-$35.92M-$20.89M
EPS (basic)-0.28-0.09
EPS (diluted)-0.28-0.09
Weighted avg. shares (diluted)230.12M200.19M
Balance sheet
Cash & equivalents$40.79M$46.35M
Short-term investments$14.99M$2.02M
Receivables$891,000$638,000
Current assets$59.16M$51.00M
PP&E, net$2.57M$2.25M
Goodwill$10.67M$10.67M
Intangibles$31.70M$46.54M
Total assets$112.58M$113.22M
Current liabilities$11.37M$13.98M
Total liabilities$69.24M$36.21M
Shareholders' equity$44.55M$78.38M
Shares outstanding243.12M220.42M
Cash flow statement
Operating cash flow-$18.92M-$23.09M
Capital expenditure$522,000$565,000
Free cash flow-$19.44M-$23.66M
Investing cash flow-$13.46M-$2.31M
Financing cash flow$26.95M$35.86M
Depreciation & amortization$699,000$587,000
Stock-based compensation$4.75M$5.08M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.